Global Endobronchial Ultrasound Biopsy Market Size By Type (Biopsy Forceps, Cytology Brushes), By Application (Hospitals, Ambulatory Surgical Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Endobronchial Ultrasound (EBUS) Biopsy Market was valued at USD 820 million in 2023 and is projected to reach USD 1.58 billion by 2031, growing at a CAGR of 8.5% during the forecast period from 2023 to 2031. The market is driven by the rising incidence of lung cancer, increasing preference for minimally invasive procedures, and advancements in diagnostic imaging technologies. EBUS biopsy is a critical diagnostic tool, especially for lung cancer and mediastinal diseases, offering real-time imaging with reduced procedural risks.

Drivers:

1. Rising Prevalence of Lung Cancer

Lung cancer remains one of the leading causes of cancer-related deaths globally. EBUS-guided biopsy plays a crucial role in early diagnosis and staging, making it an essential tool in oncology practices.

2. Shift Toward Minimally Invasive Procedures

Healthcare systems are increasingly adopting minimally invasive techniques due to lower patient morbidity, quicker recovery times, and cost-effectiveness, significantly boosting EBUS biopsy adoption.

3. Technological Advancements in Bronchoscopic Equipment

Innovations such as real-time ultrasound guidance, enhanced needle technology, and integration with AI-based imaging are expanding the accuracy and application range of EBUS biopsies.

Restraints:

1. High Cost of Equipment and Procedures

The cost of acquiring advanced EBUS systems and associated accessories can be prohibitive, especially in low-income regions, limiting broader adoption.

2. Shortage of Skilled Professionals

EBUS biopsy requires highly skilled pulmonologists or thoracic surgeons, and the limited number of trained professionals hampers wider accessibility in certain regions.

Opportunity:

1. Untapped Markets in Developing Regions

Emerging economies present significant opportunities for market growth due to rising healthcare expenditure, increased awareness about cancer screening, and expanding hospital infrastructure.

2. Integration with Artificial Intelligence and Robotic Assistance

Future integration of AI for image interpretation and robotic bronchoscopy for precision targeting represents a major growth avenue, improving diagnostic yield and procedural efficiency.

Market by System Type Insights:

The market is segmented by system type into Convex Probe EBUS (CP-EBUS) and Radial Probe EBUS (RP-EBUS). In 2023, Convex Probe EBUS dominated the market due to its application in real-time lymph node biopsy and staging of lung cancer. However, Radial Probe EBUS is expected to witness higher growth during the forecast period, driven by its utility in peripheral lung lesion diagnostics.

Market by End-use Insights:

Hospitals emerged as the largest end-use segment in 2023, accounting for over 60% of the global revenue. The integration of EBUS systems into hospital-based oncology and pulmonology departments, coupled with higher patient footfall, drives this dominance. Diagnostic centers are expected to grow rapidly due to decentralization of specialized diagnostic services and investments in standalone imaging facilities.

Market by Regional Insights:

North America led the global EBUS biopsy market in 2023, driven by high prevalence of lung cancer, robust healthcare infrastructure, and early adoption of advanced diagnostic tools. Asia-Pacific is expected to exhibit the fastest growth rate during the forecast period due to increasing government investments in cancer screening programs and growing medical tourism in countries like India, China, and South Korea.

Competitive Scenario:

Key players in the Global Endobronchial Ultrasound Biopsy Market include Olympus Corporation, Pentax Medical (HOYA Group), Fujifilm Holdings Corporation, Boston Scientific Corporation, Medi-Globe Corporation, and Veran Medical Technologies (a subsidiary of Olympus). These companies are actively engaging in product innovations, mergers, and expansion strategies.

In 2023, Olympus Corporation launched its next-gen EBUS-TBNA needle system with enhanced visualization and real-time navigation support.

In 2022, Boston Scientific expanded its interventional pulmonology portfolio by acquiring a stake in a robotic bronchoscopy startup.

Fujifilm introduced a hybrid imaging system integrating radial EBUS with AI-assisted interpretation in 2024.

Scope of Work – Global Endobronchial Ultrasound Biopsy Market

Report Metric Details

Market Size (2023) USD 820 million

Projected Market Size (2031) USD 1.58 billion

CAGR (2023-2031) 8.5%

Market Segments System Type (CP-EBUS, RP-EBUS), End-use (Hospitals, Diagnostic Centers), Region

Growth Drivers Rising lung cancer cases, preference for minimally invasive diagnostics, technological innovation

Opportunities Expansion in emerging economies, integration with AI and robotics

Key Market Developments:

2023: Olympus Corporation launched a new EBUS needle with integrated echogenic markers for improved visibility.

2022: Pentax Medical unveiled an AI-powered EBUS system designed to enhance diagnostic accuracy in lung nodule assessment.

2024: Veran Medical Technologies introduced a robotic navigation platform aimed at improving precision during bronchoscopic biopsies.

FAQs:

1. What is the current market size of the Global Endobronchial Ultrasound Biopsy Market?

The market was valued at USD 820 million in 2023.

2. What is the major growth driver of the Global Endobronchial Ultrasound Biopsy Market?

The primary growth driver is the rising prevalence of lung cancer and the shift toward minimally invasive diagnostic procedures.

3. Which is the largest region during the forecast period in the Global Endobronchial Ultrasound Biopsy Market?

North America holds the largest market share due to advanced healthcare systems and high diagnostic adoption rates.

4. Which segment accounted for the largest market share in the Global Endobronchial Ultrasound Biopsy Market?

The Convex Probe EBUS (CP-EBUS) segment held the largest share in 2023.

5. Who are the key market players in the Global Endobronchial Ultrasound Biopsy Market?

Key players include Olympus Corporation, Pentax Medical, Fujifilm Holdings, Boston Scientific, Medi-Globe Corporation, and Veran Medical Technologies.